Gilead Sciences (GILD) Equity Average (2009 - 2026)

Gilead Sciences (GILD) has reported Equity Average for 18 consecutive years, with $23.1 billion the latest figure, recorded in Q1 2026.

• Equity Average for Q1 2026 came in at $23.1 billion, up 20.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.1 billion (up 20.6% YoY), and the FY2025 annual result was $21.0 billion, changed 0.11% from the prior year.
• Equity Average was $23.1 billion for Q1 2026 at Gilead Sciences, up from $22.1 billion in the prior quarter.
• Over five years, Equity Average peaked at $23.1 billion in Q1 2026 and troughed at $17.8 billion in Q2 2024.
• Average Equity Average over 5 years is $20.5 billion, with a median of $20.6 billion recorded in 2025.
• Year-over-year, Equity Average retreated 16.35% in 2024 and climbed 20.6% in 2026.
• Over 5 years, Equity Average stood at $21.1 billion in 2022, then climbed by 6.45% to $22.5 billion in 2023, then slipped by 16.35% to $18.8 billion in 2024, then gained by 17.56% to $22.1 billion in 2025, then grew by 4.46% to $23.1 billion in 2026.
• Per Business Quant data, the three most recent Equity Average figures were $23.1 billion in Q1 2026, $22.1 billion in Q4 2025, and $20.6 billion in Q3 2025.